Table 1.
Clinical and pathologic characteristics of high-risk EC patients included in the gene-expression profiling of CTC
| Feature | n (%) | Feature | n (%) |
|---|---|---|---|
| Age (years) | |||
| Mean | 69 | ||
| FIGO Stage | Lymphovascular invasion | ||
| I | 15 (44.15) | Positive | 6 (17.6) |
| II | 2 (5.8) | Negative | 15 (44.1) |
| III | 11 (32.35) | Unknown | 13 (38.2) |
| IV | 6 (17.64) | Lymph node metastasis | |
| Histology | Positive | 12 (35.3) | |
| Endometrioid | 19 (55.9) | Negative | 20 (58.8) |
| Serous | 10 (29.4) | Unknown | 2 (5.9) |
| Clear cell | 5 (14.7) | Recurrence | |
| Grade | No | 18 (52.9) | |
| Well differentiated (G1) | 4 (11.8) | Yes | 15 (44.1) |
| Moderately differentiated (G2) | 6 (17.6) | Unknown | 1 (2.9) |
| Poorly differentiated (G3) | 21 (61.8) | First treatment | |
| Unknown | 3 (8.8) | Radiotherapy | 4 (11.8) |
| Myometrial invasion | Chemotherapy | 7 (20.6) | |
| <50% | 13 (38.2) | None | 17 (50) |
| >50% | 18 (52.9) | Unknown | 6 (17.6) |
| Unknown | 3 (8.8) |
Unknown values were considered as missing and therefore excluded from the statistical analysis.